Compare NWE & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWE | INDV |
|---|---|---|
| Founded | 1923 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.7B |
| IPO Year | 2023 | 2014 |
| Metric | NWE | INDV |
|---|---|---|
| Price | $72.09 | $38.82 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $66.50 | N/A |
| AVG Volume (30 Days) | 335.4K | ★ 2.1M |
| Earning Date | 04-29-2026 | 06-08-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | 1.43 | ★ 1.67 |
| Revenue | ★ $1,610,559,000.00 | $1,239,000,000.00 |
| Revenue This Year | $8.84 | N/A |
| Revenue Next Year | $5.31 | N/A |
| P/E Ratio | $49.14 | ★ $23.16 |
| Revenue Growth | ★ 6.38 | 4.29 |
| 52 Week Low | $54.89 | $21.83 |
| 52 Week High | $75.18 | $42.81 |
| Indicator | NWE | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 45.70 |
| Support Level | $69.08 | $38.47 |
| Resistance Level | $71.81 | $41.83 |
| Average True Range (ATR) | 1.43 | 1.74 |
| MACD | -0.30 | -0.34 |
| Stochastic Oscillator | 38.07 | 49.41 |
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric, which includes the generation, purchase, transmission, and distribution of electricity, and Natural Gas, which includes the production, purchase, transmission, storage, and distribution of natural gas. It uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric segment.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).